CSF lactate levels, τ proteins, cognitive decline: A dynamic relationship in Alzheimer's disease

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 86, Issue 6, 2015, Pages 655-659

  Liguori, C ^a   Stefani, A ^a,b   Sancesario, G ^a,b   Sancesario, G M ^a   Marciani, M G ^a,b   Pierantozzi, M ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; LACTIC ACID; PYRUVIC ACID;

ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ELECTROENCEPHALOGRAM; ENERGY METABOLISM; HUMAN; MAJOR CLINICAL STUDY; MINI MENTAL STATE EXAMINATION; MITOCHONDRION; MOLECULAR MECHANICS; MULTIINFARCT DEMENTIA; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION;

EID: 84930003182     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2014-308577     Document Type: Article

References (41)

1. Yari R, Corey-Bloom J. Alzheimer's disease. Semin Neurol 2007;27:32-41.
2. Kester MI, van der Vlies AE, Blankenstein MA, et al. CSF biomarkers predict rate of cognitive decline in Alzheimer disease. Neurology 2009;73:1353-8.
3. Wallin AK, Blennow K, Zetterberg H, et al. CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology 2010;74:1531-7.
4. Ferrer I. Altered mitochondria, energy metabolism, voltage-dependent anion channel, and lipid rafts converge to exhaust neurons in Alzheimer's disease. J Bioenerg Biomembr 2009;41:425-31.
5. Quintanilla RA, Orellana JA, von Bernhardi R. Understanding risk factors for Alzheimer's disease: interplay of neuroinflammation, connexin-based communication and oxidative stress. Arch Med Res 2012;43:632-44.
6. Manczak M, Park BS, Jung Y, et al. Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: implications for early mitochondrial dysfunction and oxidative damage. Neuromolecular Med 2004;5:147-62.
7. Manczak M, Anekonda TS, Henson E, et al. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 2006;15:1437-49.
8. Valla J, Berndt JD, Gonzalez-Lima F. Energy hypometabolism in posterior cingulate cortex of Alzheimer's patients: superficial laminar cytochromeoxidase associated with disease duration. J Neurosci 2001;21:4923-30.
9. Mosconi L, Pupi A, De Leon MJ. Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease. Ann N Y Acad Sci 2008;1147:180-95.
10. Parnetti L, Gaiti A, Polidori MC, et al. Increased cerebrospinal fluid pyruvate levels in Alzheimer's disease. Neurosci Lett 1995;199:231-3.
11. Parnetti L, Reboldi GP, Gallai V. Cerebrospinal fluid pyruvate levels in Alzheimer's disease and vascular dementia. Neurology 2000;54:735-7.
12. Redjems-Bennani N, Jeandel C, Lefebvre E, et al. Abnormal substrate levels that depend upon mitochondrial function in cerebrospinal fluid from Alzheimer patients. Gerontology 1998;44:300-4.
13. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:263-9.
14. Hachinski V, Iadecola C, Petersen RC, et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke 2006;37:2220-41.
15. Ikeuchi T, Hirayama S, Miida T, et al. Increased levels of soluble LR11 in cerebrospinal fluid of patients with Alzheimer disease. Dement Geriatr Cogn Disord 2010;30:28-32.
16. Wimo A, Reed CC, Dodel R, et al. The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries-study design and baseline findings. J Alzheimers Dis 2013;36:385-99.
17. Sancesario GM, Esposito Z, Nuccetelli M, et al. Abeta1-42 Detection in CSF of Alzheimer's disease is influenced by temperature: indication of reversible Abeta1-42 aggregation? Exp Neurol 2010;223:371-6.
18. Nunomura A, Castellani RJ, Zhu X, et al. Involvement of oxidative stress in Alzheimer disease. J Neuropathol Exp Neurol 2006;65:631-41.
19. Hirai K, Aliev G, Nunomura A, et al. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 2001;21:3017-23.
20. Chong ZZ, Li F, Maiese K. Oxidative stress in the brain: novel cellular targets that govern survival during neurodegenerative disease. Prog Neurobiol 2005;75:207-46.
21. Leuner K, Hauptmann S, Abdel-Kader R, et al. Mitochondrial dysfunction: the first domino in brain aging and Alzheimer's disease? Antioxid Redox Signal 2007;9:1659-75.
22. Mattson MP, Gleichmann M. Mitochondria in neuroplasticity and neurological disorders. Neuron 2008;60:748-66.
23. Yamada K, Toribe Y, Yanagihara K, et al. Diagnostic accuracy of blood and CSF lactate in identifying children with mitochondrial diseases affecting the central nervous system. Brain Dev 2012;34:92-7.
24. Ihara Y, Nukina N, Miura R, et al. Phosphorylated tau protein is integrated into paired helical filaments in Alzheimer's disease. J Biochem 1986;99:1807-10.
25. Gustke N, Steiner B, Mandelkow EM, et al. The Alzheimer-like phosphorylation of tau protein reduces microtubule binding and involves Ser-Pro and Thr-Pro motifs. FEBS Lett 1992;307:199-205.
26. García-Sierra F, Ghoshal N, Quinn B, et al. Conformational changes and truncation of tau protein during tangle evolution in Alzheimer's disease. J Alzheimers Dis 2003;5:65-77.
27. Tatebayashi Y, Haque N, Tung YC, et al. Role of tau phosphorylation by glycogen synthase kinase-3beta in the regulation of organelle transport. J Cell Sci 2004;117(Pt 9):1653-63.
28. La Pointe NE, Morfini G, Pigino G, et al. The amino terminus of tau inhibits kinesin-dependent axonal transport: implications for filament toxicity. J Neurosci Res 2009;87:440-51.
29. Vershinin M, Carter BC, Razafsky DS, et al. Multiple-motor based transport and its regulation by Tau. Proc Natl Acad Sci USA 2007;104:87-92.
30. Ebneth A, Godemann R, Stamer K, et al. Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: implications for Alzheimer's disease. J Cell Biol 1998;143:777-94.
31. Morel M, Authelet M, Dedecker R, et al. Glycogen synthase kinase-3beta and the p25 activator of cyclin dependent kinase 5 increase pausing of mitochondria in neurons. Neuroscience 2010;167:1044-56.
32. David DC, Hauptmann S, Scherping I, et al. Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J Biol Chem 2005;280:23802-14.
33. Götz J, Chen F, Barmettler R, et al. Tau filament formation in transgenic mice expressing P301L tau. J Biol Chem 2001;276:529-34.
34. Yao J, Irwin RW, Zhao L, et al. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 2009;106:14670-5.
35. Hauptmann S, Scherping I, Dröse S, et al. Mitochondrial dysfunction: an early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol Aging 2009;30:1574-86.
36. Kulic L, Wollmer MA, Rhein V, et al. Combined expression of tau and the Harlequin mouse mutation leads to increased mitochondrial dysfunction, tau pathology and neurodegeneration. Neurobiol Aging 2011;32:1827-38.
37. Sultana R, Ravagna A, Mohmmad-Abdul H, et al. Ferulic acid ethyl ester protects neurons against amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: relationship to antioxidant activity. J Neurochem 2005;92:749-58.
38. Butterfield DA, Gnjec A, Poon HF, et al. Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimer's disease: an initial assessment. J Alzheimers Dis 2006;10:391-7.
39. Reed T, Perluigi M, Sultana R, et al. Redox proteomic identification of 4-hydroxy-2-nonenal-modified brain proteins in amnestic mild cognitive impairment: insight into the role of lipid peroxidation in the progression and pathogenesis of Alzheimer's disease. Neurobiol Dis 2008;30:107-20.
40. Cao C, Li Y, Liu H, et al. The potential therapeutic effects of THC on Alzheimer's disease. J Alzheimer Dis 2014 Jul. 7. [Epub ahead of print].
41. Yang SY, He XY, Isaacs C, et al. Roles of 17β-hydroxysteroid dehydrogenase type 10 in neurodegenerative disorders. J Steroid Biochem Mol Biol 2014;143C:460-72.